Meghan Morris, PhD

Headshot of Meghan Morris
User Profile Photo

Meghan Morris, PhD

User Profile Name
Associate Professor, School of Medicine
CTSI Profile Title
User Profile Email

Biography

I am a mixed-method epidemiologist with graduate training in infectious disease and social epidemiology. I am interested understanding the biological, contextual, and policy aspects that place injection drug users at greater risk for HIV, hepatitis C infection and other negative health outcomes.

User Profile Bio

Displaying 1 - 25 of 58

  1. Artenie A, Facente SN, Patel S, Stone J, Hecht J, Rhodes P, McFarland W, Wilson E, Vickerman P, Morris MD. A cross-sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention. Health Sci Rep. 2022 Jul; 5(4):e704.
  2. Facente SN, Grinstein R, Bruhn R, Kaidarova Z, Wilson E, Hecht J, Burk K, Grebe E, Morris MD. Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019. PLoS One. 2022; 17(5):e0267902.
  3. Tully DC, Hahn JA, Bean DJ, Evans JL, Morris MD, Page K, Allen TM. Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships. Clin Infect Dis. 2021 Aug 27.
  4. Sarah Raifman, Michelle A. DeVost, Jean C. Digitale, Yea-Hung Chen, Meghan D. Morris. Respondent-Driven Sampling: a Sampling Method for Hard-to-Reach Populations and Beyond. Current Epidemiology Reports. 2022 Mar 1; 9(1):38-47.
  5. Mirzazadeh A, Hosseini-Hooshyar S, Shahesmaeili A, Sharafi H, Shafiei M, Zarei J, Mousavian G, Tavakoli F, Ghalekhani N, Shokoohi M, Khezri M, Mehmandoost S, Shojaei MR, Karamouzian M, Briceno A, Morris MD, Alavian SM, Haghdoost AA, Sharifi H, Page KA. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. Int J Drug Policy. 2022 04; 102:103580.
  6. Mirzazadeh A, Facente SN, Burk K, Kahn JG, Morris MD, End Hep C SF. Hepatitis C mortality trends in San Francisco: can we reach elimination targets? Ann Epidemiol. 2022 01; 65:59-64.
  7. Facente SN, Patel S, Hecht J, Wilson E, McFarland W, Page K, Vickerman P, Fraser H, Burk K, Morris MD. Hepatitis C Care Cascades for 3 Populations at High Risk: Low-income Trans Women, Young People Who Inject Drugs, and Men Who Have Sex With Men and Inject Drugs. Clin Infect Dis. 2021 Sep 15; 73(6):e1290-e1295.
  8. Dang KV, Rerolle F, Ackley SF, Irish AM, Mehta KM, Bailey I, Fair E, Miller C, Bibbins-Domingo K, Wong-Moy E, Glymour MM, Morris MD. A Randomized Study to Assess the Effect of Including the Graduate Record Examinations Results on Reviewer Scores for Underrepresented Minorities. Am J Epidemiol. 2021 09 01; 190(9):1744-1750.
  9. Mirzazadeh A, Chen YH, Lin J, Burk K, Wilson EC, Miller D, Veloso D, McFarland W, Morris MD. Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco. PLoS One. 2021; 16(4):e0249585.
  10. Arum C, Fraser H, Artenie AA, Bivegete S, Trickey A, Alary M, Astemborski J, Iversen J, Lim AG, MacGregor L, Morris M, Ong JJ, Platt L, Sack-Davis R, van Santen DK, Solomon SS, Sypsa V, Valencia J, Van Den Boom W, Walker JG, Ward Z, Stone J, Vickerman P, Homelessness, HIV, and HCV Review Collaborative Group . Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health. 2021 05; 6(5):e309-e323.
  11. Stockman JK, Syvertsen JL, Hayashi HD, Ludwig-Barron N, Tsuyuki K, Morris MD, Palinkas LA. "Violence and love and drugs…it all goes hand in hand": A mixed methods analysis of the substance abuse, violence, and HIV/AIDS syndemic among women who use methamphetamine. Subst Abus. 2021 Jan 25; 1-22.
  12. Morris MD, Yen IH, Shiboski S, Evans JL, Page K. Housing Stability and Hepatitis C Infection for Young Adults Who Inject Drugs: Examining the Relationship of Consistent and Intermittent Housing Status on HCV Infection Risk. J Urban Health. 2020 12; 97(6):831-844.
  13. Gilman SE, Arah OA, Bates LM, Branas CC, Cozier YC, Datta GD, DeVilbiss EA, Fink DS, Hajat A, Johnson DA, Lopez DS, Morris MD, Weuve J, Abuelezam NN, Diversity and Inclusion Committee of the Society for Epidemiologic Research . The Society for Epidemiologic Research and the Future of Diversity and Inclusion in Epidemiology. Am J Epidemiol. 2020 10 01; 189(10):1049-1052.
  14. DeVilbiss EA, Weuve J, Fink DS, Morris MD, Arah OA, Radoc JG, Datta GD, Abuelezam NN, Lopez DS, Johnson DA, Branas CC, Schisterman EF. Assessing Representation and Perceived Inclusion among Members in the Society for Epidemiologic Research. Am J Epidemiol. 2020 Jan 07.
  15. Geddes L, Iversen J, Wand H, Esmaeili A, Tsui J, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L, International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3) Collaborative . Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection. Clin Infect Dis. 2020 01 01; 70(1):123-131.
  16. Page K, Evans JL, Hahn JA, Vickerman P, Shiboski S, Morris MD. HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco. PLoS One. 2019; 14(12):e0226166.
  17. Esmaeili A, Shokoohi M, Danesh A, Sharifi H, Karamouzian M, Haghdoost A, Shahesmaeili A, Akbarpour S, Morris MD, Mirzazadeh A. Dual Unsafe Injection and Sexual Behaviors for HIV Infection Among People Who Inject Drugs in Iran. AIDS Behav. 2019 Jun; 23(6):1594-1603.
  18. Morris MD, Andrew E, Tan JY, Maher L, Hoff C, Darbes L, Page K. Injecting-related trust, cooperation, intimacy, and power as key factors influencing risk perception among drug injecting partnerships. PLoS One. 2019; 14(5):e0217811.
  19. Hahn JA, Tully DC, Evans JL, Morris MD, Briceno A, Bean DJ, Allen TM, Page K. Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships. Open Forum Infect Dis. 2019 Apr; 6(4):ofz125.
  20. Mooney AC, Neilands TB, Giannella E, Morris MD, Tulsky J, Glymour MM. Effects of a voter initiative on disparities in punishment severity for drug offenses across California counties. Soc Sci Med. 2019 06; 230:9-19.
  21. Morris MD, Mirzazadeh A, Evans JL, Briceno A, Coffin P, Hahn JA, Page KA. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated. Drug Alcohol Depend. 2019 05 01; 198:133-135.
  22. Facente SN, Grebe E, Burk K, Morris MD, Murphy EL, Mirzazadeh A, Smith AA, Sanchez MA, Evans JL, Nishimura A, Raymond HF, End Hep C SF . Correction: Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination. PLoS One. 2018; 13(7):e0200866.
  23. Ndayongeje J, Msami A, Laurent YI, Mwankemwa S, Makumbuli M, Ngonyani AM, Tiberio J, Welty S, Said C, Morris MD, McFarland W. Illicit Drug Users in the Tanzanian Hinterland: Population Size Estimation Through Key Informant-Driven Hot Spot Mapping. AIDS Behav. 2018 Jul; 22(Suppl 1):4-9.
  24. Mooney AC, Giannella E, Glymour MM, Neilands TB, Morris MD, Tulsky J, Sudhinaraset M. Racial/Ethnic Disparities in Arrests for Drug Possession After California Proposition 47, 2011-2016. Am J Public Health. 2018 08; 108(8):987-993.
  25. Facente SN, Grebe E, Burk K, Morris MD, Murphy EL, Mirzazadeh A, Smith AA, Sanchez MA, Evans JL, Nishimura A, Raymond HF, End Hep C SF . Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination. PLoS One. 2018; 13(4):e0195575.